Rhythm Pharmaceuticals announces setmelanotide granted BTD from FDA
In: The Fly, 2022-11-01
serialPeriodical
Zugriff:
Rhythm Pharmaceuticals announced that setmelanotide received Breakthrough Therapy Designation, BTD, from the U.S. Food and Drug Administration, FDA, for the treatment of hypothalamic obesity. 'Breakthrough Therapy Designation marks a meaningful [...]
Titel: |
Rhythm Pharmaceuticals announces setmelanotide granted BTD from FDA
|
---|---|
Zeitschrift: | The Fly, 2022-11-01 |
Veröffentlichung: | 2022 |
Medientyp: | serialPeriodical |
Schlagwort: |
|
Sonstiges: |
|